Long‐term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis

Abstract

Long-term (12-month) administration of fluticasone furoate 110 microg od revealed an AE profile typical of the intranasal corticosteroid class in both adult and adolescent patients with PAR, with no evidence of clinically relevant systemic corticosteroid exposure.

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…Intranasal glucocorticosteroids are well tolerated, and adverse effects are few in number, mild in severity and have the same incidence as placebo (1567)(1568)(1569)(1570)(1571)(1572). However, there are differences in safety between molecules, those with low bioavailability being the best tolerated (1573,1574).…”

Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study

“…The safety of fluticasone furoate nasal spray (FFNS) has been demonstrated in a 12-month study in adults/adolescents with perennial AR. 10 The objective of this study was to evaluate the safety and efficacy of two doses of FFNS (110μg once daily and 110μg twice daily) compared with placebo as monotherapy in treating adults/adolescents with uncomplicated ARS. For this study, uncomplicated ARS was defined as persistent inflammation of the paranasal sinuses and nasal cavity beyond 10 days.…”

The Effect of Combined Medical Treatment on Quality of Life in Persistent Allergic Rhinitis

“…When nasal congestion is present and is the dominating symptom; an intranasal glucocorticosteroid is suggested as the most appropriate first-line treatment [9,10]. Intranasal glucocorticosteroids are very well tolerated with low incidence of adverse effects and is comparable to placebo [11][12][13][14][15]. There may be differences in the safety of different molecules and those with lower bioavailability are better tolerated [16,17].…”